Biotechnology

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

April 7, 2025 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor (VEGF), and HS3215, a dual-target biologic binding to Human Epidermal Growth Factors 2 (HER2) and 3...

Read more

Happy Campers Adopts Earth-Friendly Food Packaging with Verde(R) Biobased, Biodegradable, & Recyclable Polyethylene(R)

April 7, 2025 6:00 AM

Verde Bioresins®, a pioneer in sustainable polymer technology, announces its partnership with Happy Campers, a leader in gluten-free organic baked goods, in the launch of Happy Campers new earth-friendly packaging made with Verde biobased, biodegradable & recyclable line of PolyEarthylene® resins. This groundbreaking, FDA compliant, packaging solution aligns with Happy Campers' ongoing commitment to sustainability and environmental stewardship. ...

Read more

Lobe Sciences Provides Corporate Update

April 4, 2025 11:50 PM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a commercial stage biopharmaceutical company focused on developing products using lipid technology to treat diseases with significant unmet medical needs is providing a corporate update with respect to certain recent transactions. The Company wishes to provide notice of the following transactions: On March 14, 2024, the Company issued C$678,450 (US$500,000)...

Read more

Data4Cure Showcases Its Knowledge Graph and AI Platform at Bio-IT

April 4, 2025 9:00 AM

Today at the Bio-IT World Conference & Expo in Boston, Data4Cure, Inc. will present its latest advancements in AI-driven data integration and knowledge discovery to support pharmaceutical research and development. In a featured session titled "An AI and Knowledge Graph Ecosystem to Inform Pharmaceutical R&D," Janusz Dutkowski, Data4Cure's CEO and Co-Founder, and Roy Ronen, CTO, will highlight how the company's Biomedical Intelligence® Cloud is...

Read more

BioInvent International AB Publishes Annual Report 2024

April 4, 2025 4:20 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2024 has been published. The Annual Report is attached to this press release in pdf format and is available on the company's website www.bioinvent.com . About BioInvent BioInvent International AB...

Read more

Jabez Biosciences, Inc. Announces First Patient Dosed in Phase 1 Oncology Clinical Study of JBZ-001

April 2, 2025 9:00 AM

Jabez Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to ushering in the future of cancer therapy, today announced that the first patient has been successfully dosed in its Phase 1 clinical study of JBZ-001, a next-generation small molecule inhibitor targeting dihydroorotate dehydrogenase (DHODH). This milestone marks a significant step forward in the company's mission to develop innovative treatments that improve and...

Read more

Notice of Annual General Meeting in Alligator Bioscience AB

April 2, 2025 3:00 AM

Alligator Bioscience (STO:ATORX) - The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the annual general meeting to be held on Wednesday 7 May 2025, at 10.00 a.m CEST at Medicon Village, conference room Bengt, Scheelevägen 4 in Lund, Sweden. RIGHT TO PARTICIPATE Shareholders that want to participate in the annual general meeting must be recorded in the company's share register kept by Euroclear Sweden AB as of...

Read more

PulpFixin Launches to Revolutionize Lab Sustainability with 100% Compostable and 100% Biodegradable Solutions

April 1, 2025 10:45 AM

PulpFixin, a groundbreaking company dedicated to transforming sustainability in the biotech and pharmaceutical supply industries, today announces its official launch. Founded by four seasoned veterans of the biotech and pharmaceutical supplies industry, PulpFixin aims to provide innovative, biodegradable alternatives to single-use plastics without compromising on quality or performance. At the forefront of this mission is the debut of...

Read more

Alligator Bioscience Determines Record Date for Reverse Share Split of Ordinary Shares and Reminds of the Recalculation of Warrants

April 1, 2025 9:45 AM

Alligator Bioscience (STO:ATORX) - The board of directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company") has resolved that the record date for the reverse share split of ordinary shares that was resolved upon at the extraordinary general meeting on 27 March 2025 shall be 8 April 2025. Furthermore, as previously communicated, a recalculation of the terms and conditions of the Company's warrants series TO 12 and TO 13 will be...

Read more

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

April 1, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation in Alzheimer's dementia, to MIND Institute at Miami Jewish Health in Miami, Florida. This addition further advances the company's efforts to accelerate the trial's completion and builds on promising interim data suggesting the potential of IGC-AD1 to improve patient outcomes. Miami Jewish...

Read more

BioInvent to Participate in Upcoming Investor Conferences

April 1, 2025 5:20 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that during April, the Company management team will participate in the following upcoming investor conferences: Van Lanschot Kempen Life Sciences Conference Format: One-on-one meetings Date: April 2 Location: Amsterdam, The...

Read more

Elizabeth Fraley, CEO of Kinder Ready, Offers an Expert Guide to Help Families Choose the Right Private School for Their Children's Needs

March 31, 2025 5:00 PM

Recognizing the complexities of this process, Elizabeth Fraley Kinder Ready has released an expert guide designed to help families navigate the overwhelming task of choosing a private school that aligns with their child's academic, emotional, and social development needs. Leveraging her extensive experience in early childhood education, she has developed a comprehensive resource to simplify decision-making for parents. Through personalized...

Read more

Elizabeth Fraley, CEO of Kinder Ready, Launches Proven Strategies to Boost Early Mathematics for Young Learners

March 31, 2025 4:45 PM

Spearheaded by Elizabeth Fraley Kinder Ready, CEO and educational visionary, this program introduces a series of proven, research-backed strategies to build confidence, mastery, and enthusiasm for mathematics during the critical foundational years. Recognizing a national gap in early math readiness, Kinder Ready Elizabeth Fraley has developed a new approach that integrates structured math instruction with engaging, play-based learning. The...

Read more

Change in Number of Shares and Votes in Alligator Bioscience AB

March 31, 2025 9:10 AM

Alligator Bioscience (STO:ATORX) During March 2025, the number of shares and votes in Alligator Bioscience AB ("Alligator Bioscience") has increased as a result of the rights issue of units which was resolved by the Board of Directors on 2 December 2024 and approved by the extraordinary general meeting on 13 January 2025, as well as the directed issue of units to guarantors in the rights issue resolved by the Board of Directors on 20 February...

Read more

ONI's LNP Profiler Kit With AutoLNP: Revolutionizing Lipid Nanoparticle Characterization With Super-Resolution Microscopy

March 31, 2025 9:00 AM

Oxford Nanoimaging (ONI), a leader in super-resolution microscopy, is revolutionizing lipid nanoparticle (LNP) analysis with the launch of the ONI Application Kit™: LNP Profiler, the first and only verified solution within the SMLM and super-resolution space for particle analysis. The kit includes a fully integrated platform for quantitative particle research, with optimized reagents, precision imaging hardware, and advanced software to deliver...

Read more

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

March 31, 2025 9:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced its abstract has been accepted for presentation at the Society for Clinical Vascular Surgery (SCVS) 52nd Annual Symposium being held March 29-April 2, 2025 in Austin, TX. As part of the SCVS Symposium, Dr. Cassius Iyad Ochoa Chaar, Associate Professor of Surgery, Yale School of...

Read more

International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results

March 31, 2025 8:30 AM

International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2024. FY 2024 Financial Highlights: Revenues increased to $9.09 million in 2024, an...

Read more

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

March 31, 2025 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed indication of moderate-to-severe chronic pruritus in patients with primary biliary cholangitis ("PBC"), which utilizes an approved active ingredient, now formulated as a buccal film, Tharimmune is seeking to develop TH104 for the additional...

Read more

Aspira Receives $1.5 million Milestone Payment from the ARPA-H Sprint for Women’s Health Award

March 31, 2025 8:00 AM

Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the second development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result of satisfying the second development milestone, Aspira received a $1.5 million cash payment under the terms of the related...

Read more

Lifeloc Technologies Reports 2024 Full Year Results

March 28, 2025 6:10 PM

Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol testing devices, has announced financial results for the 2024 fiscal year ended December 31, 2024. 2024 Financial Highlights Lifeloc Technologies posted annual net revenue of $8.538 million resulting in a net loss of ($1.053) million in 2024, or ($0.41) per diluted share. These results compare to net revenue of $9.330 million for...

Read more